Literature DB >> 18392744

Liver cell transplantation for the treatment of inborn errors of metabolism.

J Meyburg1, G F Hoffmann.   

Abstract

Over the last 15 years, liver cell transplantation (LCT) has developed from an experimental laboratory technique to a potentially life-saving therapeutic option. Because of its minimally invasive nature, the method is especially attractive for (small) children. In children with liver-based inborn errors of metabolism, this transfer of enzyme activity can be regarded as a gene therapy, which can be installed independently and additionally to conservative treatment concepts. To date 14 children with inherited metabolic diseases have undergone LCT in various centres. Although individual results are encouraging, different treatment protocols, difficulties in the objective assessment of function of the transplant, and finally the lack of a controlled study make it difficult to judge the overall significance of LCT in the treatment of metabolic diseases and call for collaborative clinical research.

Entities:  

Mesh:

Year:  2008        PMID: 18392744     DOI: 10.1007/s10545-008-0829-6

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  52 in total

1.  Hepatocyte transplantation as a treatment for glycogen storage disease type 1a.

Authors:  Maurizio Muraca; Giorgio Gerunda; Daniele Neri; Maria-Teresa Vilei; Anna Granato; Paolo Feltracco; Muzio Meroni; Gianpiero Giron; Alberto B Burlina
Journal:  Lancet       Date:  2002-01-26       Impact factor: 79.321

2.  Expression of human alpha 1-antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes.

Authors:  M A Kay; P Baley; S Rothenberg; F Leland; L Fleming; K P Ponder; T Liu; M Finegold; G Darlington; W Pokorny
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

3.  Intraportal hepatocyte transplantation in the pig: hemodynamic and histopathological study.

Authors:  Maurizio Muraca; Danielle Neri; Anna Parenti; Paolo Feltracco; Anna Granato; Maria Therese Vilei; Chiara Ferraresso; Roberto Ballarin; Gian Eros Zanusso; Gianpiero Giron; Jacek Rozga; Giorgio Gerunda
Journal:  Transplantation       Date:  2002-03-27       Impact factor: 4.939

4.  Regional and transient ischemia/reperfusion injury in the liver improves therapeutic efficacy of allogeneic intraportal hepatocyte transplantation in low-density lipoprotein receptor deficient Watanabe rabbits.

Authors:  Masoumeh Attaran; Andrea Schneider; Christiane Grote; Caroline Zwiens; Peer Flemming; Klaus F Gratz; Andrea Jochheim; Matthias J Bahr; Michael P Manns; Michael Ott
Journal:  J Hepatol       Date:  2004-11       Impact factor: 25.083

Review 5.  Current role of liver transplantation for the treatment of urea cycle disorders: a review of the worldwide English literature and 13 cases at Kyoto University.

Authors:  Daisuke Morioka; Mureo Kasahara; Yasutsugu Takada; Yasumasa Shirouzu; Kaoru Taira; Seisuke Sakamoto; Kenji Uryuhara; Hiroto Egawa; Hiroshi Shimada; Koichi Tanaka
Journal:  Liver Transpl       Date:  2005-11       Impact factor: 5.799

6.  Sustained engraftment and tissue enzyme activity after liver cell transplantation for argininosuccinate lyase deficiency.

Authors:  Xavier Stéphenne; Mustapha Najimi; Catherine Sibille; Marie-Cécile Nassogne; Françoise Smets; Etienne M Sokal
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

7.  Hepatocyte transplantation in a 4-year-old girl with peroxisomal biogenesis disease: technique, safety, and metabolic follow-up.

Authors:  Etienne M Sokal; Françoise Smets; Annick Bourgois; Lionel Van Maldergem; Jean-Paul Buts; Raymond Reding; Jean Bernard Otte; Veerle Evrard; Dominique Latinne; Marie Françoise Vincent; Anne Moser; Humberto E Soriano
Journal:  Transplantation       Date:  2003-08-27       Impact factor: 4.939

8.  Engraftment assessment in human and mouse liver tissue after sex-mismatched liver cell transplantation by real-time quantitative PCR for Y chromosome sequences.

Authors:  Ling-Jia Wang; Yong Ming Chen; David George; Francois Smets; Etienne M Sokal; Eric G Bremer; Humberto E Soriano
Journal:  Liver Transpl       Date:  2002-09       Impact factor: 5.799

9.  Survival after treatment with phenylacetate and benzoate for urea-cycle disorders.

Authors:  Gregory M Enns; Susan A Berry; Gerard T Berry; William J Rhead; Saul W Brusilow; Ada Hamosh
Journal:  N Engl J Med       Date:  2007-05-31       Impact factor: 91.245

10.  Gene expression of urea cycle enzymes following two-thirds partial hepatectomy in the rat.

Authors:  N Tygstrup; S Bak; B Krog; A Pietrangelo; D A Shafritz
Journal:  J Hepatol       Date:  1995-03       Impact factor: 25.083

View more
  4 in total

Review 1.  Transplantation as disease modifying therapy in adults with inherited metabolic disorders.

Authors:  Sandra Sirrs; Fady Hannah-Shmouni; Stephen Nantel; James Neuberger; Eric M Yoshida
Journal:  J Inherit Metab Dis       Date:  2018-02-01       Impact factor: 4.982

Review 2.  Stem cells for liver repopulation.

Authors:  Alejandro Soto-Gutierrez; Nalu Navarro-Alvarez; Hiroshi Yagi; Martin L Yarmush
Journal:  Curr Opin Organ Transplant       Date:  2009-12       Impact factor: 2.640

3.  Primary Human Hepatocytes Repopulate Livers of Mice After In Vitro Culturing and Lentiviral-Mediated Gene Transfer.

Authors:  Jeanette Bierwolf; Tassilo Volz; Marc Lütgehetmann; Lena Allweiss; Kristoffer Riecken; Michael Warlich; Boris Fehse; Joerg C Kalff; Maura Dandri; Joerg-Matthias Pollok
Journal:  Tissue Eng Part A       Date:  2016-05       Impact factor: 3.845

4.  Investigation of Clinical Safety of Human iPS Cell-Derived Liver Organoid Transplantation to Infantile Patients in Porcine Model.

Authors:  Tomonori Tsuchida; Soichiro Murata; Shunsuke Hasegawa; Satoshi Mikami; Shin Enosawa; Huai-Che Hsu; Akinari Fukuda; Satoshi Okamoto; Akihiro Mori; Megumi Matsuo; Yumi Kawakatsu; Hitomi Matsunari; Kazuaki Nakano; Hiroshi Nagashima; Hideki Taniguchi
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.